American Academy of Pediatrics Committee on Fetus and Newborn
Id called it early for the year on policy analysis other than the CMS ACCESS model
6x more weight loss than exercise and diet alone Lose an average of 18% of your body weight 93% kept the weight off for good * Data based on RaeRx patients over their first 6 months of treatment We will fix your broken metabolism
Otherwise, the price of shipping is calculated on the checkout page
100% fees at risk* 0% GLP-1 for weight loss trend guarantee 8% bodyweight reduction, with or without GLP-1 medications More than just marketing claims, validated weight loss results Years of nutrition-first care, medication management, and GLP-1 deprescription when clinically appropriate Learn about our approach Weight loss without drugs View our outcomes Sustained weight loss a year after GLP-1 deprescription See the results How it works Easy implementation via PBM integrations enables guardrails without rebate impact Navigate members to Virtas effective care via our PBM integrations and member communications Educate on the benefits of Nutrition Therapy and guide each member to the right care with or without GLP-1s Adapt nutrition and behavioral care to each member based on lifestyle, metabolism, and continuous health data Maximize success for those on GLP-1s with provider-led effective titration, side-effect support, and engagement monitoringno wasted spend on off-label prescriptions or ineffective anti-obesity medications
Dual and triple GLP-1 agonists are next-generation therapies that activate multiple receptors to enhance metabolic effects
